Automate Your Wheel Strategy on STXS
With Tiblio's Option Bot, you can configure your own wheel strategy including STXS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol STXS
- Rev/Share 0.3134
- Book/Share 0.0932
- PB 68.2651
- Debt/Equity 2.0375
- CurrentRatio 1.0695
- ROIC -1.1704
- MktCap 202162016.0
- FreeCF/Share -0.0907
- PFCF -25.3845
- PE -7.6574
- Debt/Assets 0.1284
- DivYield 0
- ROE -2.1713
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Stereotaxis Announces $12.5 Million Registered Direct Offering of Common Stock
Published: July 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
ST. LOUIS, July 17, 2025 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it has entered into definitive agreements with investors for the sale of approximately $12.5 million of its shares of common stock in a registered direct offering, at a price per share of $2.00. The financing is being led by a strategic industry partner along with participation from a select group of institutional investors.
Read More
Stereotaxis Reports Positive Initial Data From MAGiC Catheter Trial
Published: July 07, 2025 by: Zacks Investment Research
Sentiment: Positive
STXS posts first peer-reviewed results for its MAGiC catheter, showing 94% efficacy and strong safety in arrhythmia treatment.
Read More
First Clinical Results from MAGiC Catheter Study Published in the Journal of Interventional Cardiac Electrophysiology
Published: July 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
ST. LOUIS, July 01, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the publication of initial clinical results using the MAGiC catheter in the Journal of Interventional Cardiac Electrophysiology. Titled “First In‑Human Results of the MAGiC Robotic Magnetic Navigation Radiofrequency Ablation Catheter,” the publication is the first peer-reviewed literature supporting the efficacy and safety of Stereotaxis' MAGiC catheter.
Read More
Stereotaxis to Report First Quarter 2025 Financial Results on May 12, 2025
Published: April 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
ST. LOUIS, April 22, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 first quarter on Monday, May 12, 2025 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss the Company's results and corporate developments.
Read More
Stereotaxis to Feature First-Ever Live Demo of GenesisX Robotic System at HRS 2025
Published: April 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
ST. LOUIS, April 21, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, announced today it will host a live demonstration of the GenesisX Robotic System at this year's Heart Rhythm Symposium (HRS), taking place April 24 – 27 in San Diego, CA. This marks the first live, public demonstration of GenesisX, offering a glimpse to HRS attendees into the robot's revolutionary clinical capabilities and “weekend” installation.
Read More
Stereotaxis To Get FDA Approval Of MAGiC This Fall, Ending Cash Burn
Published: March 07, 2025 by: Seeking Alpha
Sentiment: Positive
I addressed the bearish concerns some investors have. Management's conservative 2025 sales guidance set beatable targets, focusing on the existing system backlog and MAGiC usage in Europe. MAGiC Sweep will generate significant recurring revenue per procedure and expand the advantages of using robotics in EP.
Read More
STXS Stock Tumbles Despite EMAGIN Catheter Submission for Approval
Published: March 04, 2025 by: Zacks Investment Research
Sentiment: Negative
Stereotaxis submits EMAGIN 5F, a robotic catheter, for regulatory clearance.
Read More
Stereotaxis Inc. (STXS) Reports Q4 Loss, Lags Revenue Estimates
Published: March 03, 2025 by: Zacks Investment Research
Sentiment: Negative
Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.07 per share a year ago.
Read More
Stereotaxis to Present at 45th Annual TD Cowen Healthcare Conference
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
ST. LOUIS, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will participate in TD Cowen's 45th Annual Healthcare Conference in Boston, Massachusetts.
Read More
About Stereotaxis, Inc. (STXS)
- IPO Date 2004-08-12
- Website https://www.stereotaxis.com
- Industry Medical - Instruments & Supplies
- CEO David Leo Fischel C.A.I.A.,
- Employees 139